Pre-ablation stimulated thyroglobulin to TSH ratio as a strong predictor of non-generally satisfactory response to initial radioiodine therapy in papillary thyroid carcinoma patients undergoing lateral neck dissection

Key Points

• A pre-ablation thyroglobulin to TSH ratio above 0.127 indicates a higher risk of unsatisfactory therapy response.
• The analysis leverages ATA recurrence risk categories for better prediction of treatment outcomes.
• Observational pilot study shows promise in using pre-sTg/TSH ratio for personalized follow-up strategies.
• Supports the need for further validation in larger, multi-center cohorts for broader applicability.